Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2009 1
2010 1
2013 1
2015 1
2016 1
2018 2
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic factor in patient with recurrent pancreatic adenocarcinoma.
Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Otsuka H, Baba K, Serikawa M, Ishii Y, Tsuboi T, Arihiro K, Murakami Y, Murashita J, Takahashi S. Sumiyoshi T, et al. Langenbecks Arch Surg. 2023 Sep 2;408(1):347. doi: 10.1007/s00423-023-03073-2. Langenbecks Arch Surg. 2023. PMID: 37658871
Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma.
Reddy AV, Hill CS, Sehgal S, He J, Zheng L, Herman JM, Meyer J, Narang AK. Reddy AV, et al. Clin Oncol (R Coll Radiol). 2022 Jun;34(6):386-394. doi: 10.1016/j.clon.2021.12.014. Epub 2021 Dec 31. Clin Oncol (R Coll Radiol). 2022. PMID: 34974972
AIMS: The purpose of this study was to report on outcomes of a cohort of patients who were treated with reirradiation with stereotactic body radiation therapy (SBRT) for locally recurrent pancreatic adenocarcinoma. MATERIALS AND METHODS: Patients treated with …
AIMS: The purpose of this study was to report on outcomes of a cohort of patients who were treated with reirradiation with stereotactic body …
Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
Makita K, Kamigaki T, Okada S, Matsuda E, Ibe H, Oguma E, Naitoh K, Takimoto R, Goto S. Makita K, et al. Anticancer Res. 2018 Jul;38(7):4353-4360. doi: 10.21873/anticanres.12736. Anticancer Res. 2018. PMID: 29970573
BACKGROUND/AIM: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic adenocarcinoma and 50 patients with curatively resected pancreatic adenocarcinoma. ...
BACKGROUND/AIM: The past 17 years, immune-cell therapy has been administered to 990 patients with advanced or recurrent pancreatic …
Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P. Rayamajhi S, et al. Abdom Radiol (NY). 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z. Abdom Radiol (NY). 2018. PMID: 28900703
We evaluated the utility of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and contrast-enhanced computed tomography (CECT) in the diagnosis of recurrent pancreatic adenocarcinoma in conjunction with the tumor marke …
We evaluated the utility of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and contrast-enhanced …
18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, Richards WO, Wright JK, Frexes ME, Pinson CW, Leach SD. Rose DM, et al. Ann Surg. 1999 May;229(5):729-37; discussion 737-8. doi: 10.1097/00000658-199905000-00016. Ann Surg. 1999. PMID: 10235532 Free PMC article. Review.
OBJECTIVE: To assess the accuracy and clinical impact of 18fluorodeoxyglucose-positron emission tomography (18FDG-PET) on the management of patients with suspected primary or recurrent pancreatic adenocarcinoma, and to assess the utility of 18FDG-PET in gradi …
OBJECTIVE: To assess the accuracy and clinical impact of 18fluorodeoxyglucose-positron emission tomography (18FDG-PET) on the management of …
Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer.
Chang SC, Hsu CP, Tsai CY, Liu YY, Liu KH, Hsu JT, Yeh TS, Yeh CN, Hwang TL. Chang SC, et al. Medicine (Baltimore). 2016 Jul;95(30):e4191. doi: 10.1097/MD.0000000000004191. Medicine (Baltimore). 2016. PMID: 27472688 Free PMC article.
The median survival times were comparable in patients with recurrent pancreatic adenocarcinoma who received surgery and those who did not (DFS 10.6 vs 6.1 months, P = 0.226; OS 23.7 vs 14.0 months, P = 0.074; PRS 8.9 vs 5.8 months, P = 0.183). ...In patients …
The median survival times were comparable in patients with recurrent pancreatic adenocarcinoma who received surgery and …
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Goulart BH, Clark JW, Lauwers GY, Ryan DP, Grenon N, Muzikansky A, Zhu AX. Goulart BH, et al. J Hematol Oncol. 2009 Mar 16;2:13. doi: 10.1186/1756-8722-2-13. J Hematol Oncol. 2009. PMID: 19291303 Free PMC article.
We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations. METHODS: We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcit …
We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations. MET …
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Tozzi A, Comito T, Alongi F, Navarria P, Iftode C, Mancosu P, Reggiori G, Clerici E, Rimassa L, Zerbi A, Fogliata A, Cozzi L, Tomatis S, Scorsetti M. Tozzi A, et al. Radiat Oncol. 2013 Jun 21;8:148. doi: 10.1186/1748-717X-8-148. Radiat Oncol. 2013. PMID: 23799996 Free PMC article.
METHODS: Between January 2010 and October 2011, 30 patients with unresectable or recurrent pancreatic adenocarcinoma underwent exclusive SBRT. Twenty-one patients (70%) presented with unresectable locally advanced disease and 9 patients (30%) showed local rec …
METHODS: Between January 2010 and October 2011, 30 patients with unresectable or recurrent pancreatic adenocarcinoma un …
Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report.
Doty DG, Chuong MD, Gomez AG, Bryant J, Contreras J, Romaguera T, Alvarez D, Kotecha R, Mehta MP, Gutierrez AN, Mittauer KE. Doty DG, et al. Med Dosim. 2021 Winter;46(4):384-388. doi: 10.1016/j.meddos.2021.04.006. Epub 2021 Jun 11. Med Dosim. 2021. PMID: 34120803
Herein, we report the first use of online adaptive radiotherapy in the reirradiation setting, specifically for treatment of locally recurrent pancreatic adenocarcinoma through SMART reirradiation (SMART reRT). ...
Herein, we report the first use of online adaptive radiotherapy in the reirradiation setting, specifically for treatment of locally recur …
12 results